Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-371-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.36 million
Profitability
Miscellaneous
Employees36
OptionableNot Optionable
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health Inc (NASDAQ:JAGX) issued its quarterly earnings data on Monday, November, 19th. The biotechnology company reported ($0.61) earnings per share for the quarter. The biotechnology company had revenue of $1.13 million for the quarter. Jaguar Health had a negative net margin of 908.28% and a negative return on equity of 259.67%. View Jaguar Health's Earnings History.
When is Jaguar Health's next earnings date?
Has Jaguar Health been receiving favorable news coverage?
News headlines about JAGX stock have trended very positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jaguar Health earned a news impact score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Are investors shorting Jaguar Health?
Jaguar Health saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 158,314 shares, a decline of 70.7% from the December 14th total of 539,754 shares. Based on an average daily trading volume, of 521,907 shares, the short-interest ratio is presently 0.3 days. Currently, 0.8% of the company's shares are sold short. View Jaguar Health's Current Options Chain.
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include KemPharm (KMPH), Synergy Pharmaceuticals (SGYP), Tetraphase Pharmaceuticals (TTPH), Zynerba Pharmaceuticals (ZYNE), Immune Design (IMDZ), Merrimack Pharmaceuticals (MACK), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Sienna Biopharmaceuticals (SNNA), Otonomy (OTIC), BIOLINERX LTD/S (BLRX), Neos Therapeutics (NEOS), Achaogen (AKAO), IntelGenx Technologies (IGXT) and Innovate Biopharmaceuticals (INNT).
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
- Ms. Karen S. Wright, CFO & Treasurer (Age 63)
- Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
- Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
- Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel
When did Jaguar Health IPO?
(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $0.27.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $17.52 million and generates $4.36 million in revenue each year. Jaguar Health employs 36 workers across the globe.
What is Jaguar Health's official website?
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
